Key takeaway: Gujarat Themis Biosyn Limited (GTBL) reported a strong start to the financial year 2026-27, with a 22.1% year-on-year increase in top line to Rs. 43.8 crores and a 49.4% rise in EBITDA to Rs. 20.8 crores. Management highlighted stable demand and improved margins due to higher sales volumes. The company made significant progress in inorganic expansion, acquiring Sanofi's brands and MicroBiopharm in Japan, which are anticipated to enhance its distribution networks and manufacturing capabilities. GTBL's new R&D and API units are operational, and a hybrid power plant is under development to reduce power costs and carbon footprint. The earnings presentation also noted that the EPS for the quarter was Rs. 1.02. Overall, the document emphasized growth and strategic initiatives in expanding product offerings and geographical reach.

Key takeaway: Gujarat Themis Biosyn Limited (GTBL) provided an investor presentation detailing its recent acquisitions and strategic initiatives. The company announced the acquisition of MicroBiopharm Japan and a select product portfolio from Sanofi, both subject to regulatory approvals. GTBL aims to enhance its product offerings in tuberculosis and anti-infectives, with a focus on markets in the Middle East, Africa, and Europe. The presentation highlighted the company's expansion in research and development capabilities, including a new lab in Valsad, Gujarat, and an increase in fermentation capacity. Financially, GTBL reported a revenue from operations of INR 16,582.28 lakhs for FY26, with an EBITDA margin of 45.55%. The company emphasized its commitment to geographical diversification and forward integration strategies to improve margins and operational efficiency.

Key takeaway: Gujarat Themis Biosyn Limited (GTBL) reported a strong fiscal year-end performance, with sales volumes driven by resilient market demand. Management highlighted a 17% year-on-year revenue growth in Q4 FY26, reaching Rs. 44.2 crores, and a 20.7% increase in EBITDA to Rs. 19.4 crores. The company announced strategic acquisitions, including a portfolio of 13 brands from Sanofi, enhancing its presence in tuberculosis and anti-infective therapies, and the acquisition of MicroBiopharm Japan Co., Ltd., which expands its capabilities in biologics and fermentation. GTBL's R&D expenditure was approximately 9% of its topline, and it is establishing a hybrid power plant to reduce costs and carbon footprint. The presentation also noted a decrease in PAT margin and EPS for the quarter and full year, reflecting rising costs. Overall, GTBL emphasized its growth trajectory and ongoing expansion initiatives.

Key takeaway: Gujarat Themis Biosyn Limited (GTBL) reported an agreement to acquire a select product portfolio from Sanofi, focusing on tuberculosis and anti-infectives. The deal, valued at approximately EURO 158 million, is structured as an asset acquisition, which includes brands, marketing authorizations, dossiers, and inventory, but does not involve the transfer of manufacturing facilities or employees. Management highlighted that the acquisition would provide immediate access to regulated and semi-regulated markets, leveraging established brand equity and potential for forward integration. The presentation noted that the portfolio generated around EURO 62 million in revenue for FY 2025 and emphasized the strategic importance of this acquisition in enhancing GTBL's margin profile and operational efficiency. Management stated that this move would extend patient reach and establish a global footprint for their specialized offerings, while also aiming to unlock value through various strategic initiatives post-closing.

Key takeaway: Gujarat Themis Biosyn Limited (GTBL) reported a 10% year-on-year growth in revenue for Q3 FY26, reaching Rs. 43.4 crores, with EBITDA increasing by 12.9% to Rs. 21.31 crores. Profit After Tax (PAT) was Rs. 12.5 crores, reflecting a slight decrease from the previous year. Management highlighted that consistent sales volumes and cost optimizations contributed to stable margins despite rising manpower costs. The company completed a new fermentation facility, enhancing production capacity and supporting ongoing product development, with R&D expenditures at approximately 3% of revenue. Additionally, GTBL is establishing a hybrid power plant to reduce energy costs and carbon footprint. For the nine-month period, total income from operations grew by 7.54% to Rs. 121.70 crores, while PAT decreased by 2.67% to Rs. 35.79 crores. The presentation emphasized the company's focus on expanding its product portfolio and forward integration into API production.